Keyword: Ozempic (semaglutide)
Novo Nordisk’s oral semaglutide is heading toward a market shake-up. And the company wants to see that happen sooner rather than later.
All eyes are on Eli Lilly’s Trulicity as it faces down new competition. But the drugmaker just notched an important trial win that shows it can hang with its rival.
Novo will reduce headcount by 1,300 by the end of 2018 to feed resources into its drug launches and marketing, as well as R&D.
Novo Nordisk rolled out more data for its next great hope: oral semaglutide, which would be the only pill in a hotly competitive GLP-1 class.
Novo Nordisk is firing up its first innovation challenge to scout out tech solutions in diabetes.
Move over, Siri and Alexa: There’s a new voice in town. Meet Sophia, Novo Nordisk’s first chatbot built specifically for people with diabetes.
Pharma's summer TV advertising ended with the same old story for the most part, but a new drug on the top-10 list might shake things up.
The 2018 European Society of Cardiology Congress presented some bombshell data that would shake up the cardiovascular landscape in the coming year.
The approval case for Novo Nordisk’s oral diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
As Novo Nordisk’s highly anticipated semaglutide nears the market, the company has a big decision to make: How will it price the product?